Orchestra BioMed Inc. (OBIO)
Company Description
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company.
The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.
Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions.
The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease.
Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
| Country | United States |
| IPO Date | Aug 4, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 70 |
| CEO | David P. Hochman |
Contact Details
Address: 150 Union Square Drive New Hope, Pennsylvania United States | |
| Website | https://orchestrabiomed.com |
Stock Details
| Ticker Symbol | OBIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001814114 |
| CUSIP Number | 68572M106 |
| ISIN Number | US68572M1062 |
| Employer ID | 00-0000000 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| David P. Hochman | Founder, Chairman of the Board of Directors & Chief Executive Officer |
| Andrew Lawrence Taylor M.B.A. | Chief Financial Officer |
| Darren R. Sherman | Founder, President, Chief Operating Officer & Director |
| Dr. Yuval Hay Mika D.Sc, Ph.D. | GM & Chief Technology Officer of Bioelectronic Therapies |
| Bob Laughner | Senior Vice President of Regulatory & Quality |
| Dr. Avraham Matityahu Fischer M.D. | Senior Vice President of Medical Affairs & Innovation |
| Dr. Hans-Peter Stoll M.D., Ph.D. | Chief Clinical Officer |
| Juan Lorenzo | Senior Vice President of Product Development |
| Mark Pomeranz | GM & Executive Vice President of Interventional Therapies |
| William Reed Little | Executive Vice President of Corporate Development & Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 01, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| May 01, 2025 | 4 | Filing |
| Apr 30, 2025 | ARS | Filing |
| Apr 30, 2025 | DEFA14A | Filing |
| Apr 30, 2025 | DEF 14A | Filing |
| Apr 29, 2025 | 4 | Filing |
| Apr 29, 2025 | 8-K | Current Report |
| Apr 29, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Apr 04, 2025 | 4 | Filing |
| Apr 04, 2025 | 4 | Filing |